Core Viewpoint - The National Healthcare Security Administration (NHSA) of China has announced the 11th batch of centralized drug procurement, set to open bids on October 21 in Shanghai, covering 55 varieties and 162 specifications of drugs, including key areas such as antiviral drugs and innovative treatments for kidney diseases [1] Group 1: Procurement Details - The procurement will include various dosage forms such as oral sustained-release formulations, inhalants, and topical patches [1] - The new procurement scheme emphasizes principles of "stabilizing clinical use, ensuring quality, preventing collusion, and countering internal competition" [1] Group 2: Price Control Mechanism - A significant highlight of this round of procurement is the optimization of the price difference control "anchor," which aims to ensure fairness by controlling the price difference of selected bids [1] - The new approach will prevent individual companies from submitting abnormally low bids that could disrupt normal pricing, thus avoiding the previous phenomenon where drug prices dropped to mere cents [1]
第十一批药品集采下月开标 专家：这是集采实施7年来一个里程碑批次
Jing Ji Guan Cha Wang·2025-09-21 23:54